HK1207070A1 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]- benzoic acid 3-[5-(2-)-[124]-3-]- - Google Patents
Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]- benzoic acid 3-[5-(2-)-[124]-3-]-Info
- Publication number
- HK1207070A1 HK1207070A1 HK15107681.2A HK15107681A HK1207070A1 HK 1207070 A1 HK1207070 A1 HK 1207070A1 HK 15107681 A HK15107681 A HK 15107681A HK 1207070 A1 HK1207070 A1 HK 1207070A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oxadiazol
- fluorophenyl
- benzoic acid
- crystalline forms
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84732606P | 2006-09-25 | 2006-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207070A1 true HK1207070A1 (en) | 2016-01-22 |
Family
ID=39123850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107681.2A HK1207070A1 (en) | 2006-09-25 | 2015-08-10 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]- benzoic acid 3-[5-(2-)-[124]-3-]- |
Country Status (29)
| Country | Link |
|---|---|
| US (10) | US7863456B2 (fr) |
| EP (2) | EP2559689B1 (fr) |
| JP (6) | JP5714228B2 (fr) |
| KR (1) | KR101430144B1 (fr) |
| CN (3) | CN101541770A (fr) |
| AR (2) | AR062963A1 (fr) |
| AU (1) | AU2007300542B2 (fr) |
| BR (1) | BRPI0717107A2 (fr) |
| CA (1) | CA2663574C (fr) |
| CL (1) | CL2007002743A1 (fr) |
| DK (1) | DK2076501T3 (fr) |
| ES (2) | ES2563958T3 (fr) |
| HK (1) | HK1207070A1 (fr) |
| HU (1) | HUE028503T2 (fr) |
| IL (1) | IL197717A (fr) |
| LT (1) | LTC2076501I2 (fr) |
| MX (2) | MX344418B (fr) |
| MY (1) | MY191209A (fr) |
| NO (1) | NO341858B1 (fr) |
| NZ (1) | NZ575795A (fr) |
| PE (3) | PE20151445A1 (fr) |
| PL (2) | PL2076501T3 (fr) |
| PT (1) | PT2076501E (fr) |
| SG (2) | SG10201609581TA (fr) |
| SI (1) | SI2076501T1 (fr) |
| TW (2) | TWI452038B (fr) |
| UA (1) | UA99600C2 (fr) |
| WO (1) | WO2008039431A2 (fr) |
| ZA (1) | ZA200901949B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3345895T1 (sl) | 2003-04-11 | 2020-03-31 | Ptc Therapeutics, Inc. | Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne in zdravljenje bolezni |
| ES2390804T3 (es) * | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido |
| EP2387995A1 (fr) * | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Procédés pour la production d'une protéine fonctionnelle à partir d'ADN ayant une mutation non-sens et traitement de troubles associés |
| EP2559689B1 (fr) * | 2006-09-25 | 2017-11-29 | PTC Therapeutics, Inc. | Procédé de préparation pour formes cristallines de l'acide 3-[5-(2-fluorophényl)-[1,2,4]oxadiazol-3-yl] benzoïque |
| RS54025B1 (en) | 2006-10-12 | 2015-10-30 | Ptc Therapeutics Inc. | DOSAGE PROCEDURES FOR ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENS MUTATION SUPPRESSION THERAPY |
| PT2544679T (pt) | 2010-03-12 | 2019-07-11 | Omeros Corp | Inibidores de pde-10 e composições e métodos relacionados |
| WO2014153643A1 (fr) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions et procédés d'utilisation associés dans le traitement de l'aniridie |
| WO2014165673A1 (fr) | 2013-04-03 | 2014-10-09 | Colorado Energy Research Technologies, LLC | Procédés et systèmes pour produire des aldéhydes à partir d'huiles de graines organiques |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| CA2942147C (fr) | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Compositions pharmaceutiques et sels d'un acide benzoique 1,2,4-oxadiazole |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| KR101703137B1 (ko) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
| MY196130A (en) | 2015-03-10 | 2023-03-16 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators |
| US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| AR106530A1 (es) | 2015-10-30 | 2018-01-24 | Ptc Therapeutics Inc | Métodos para tratar epilepsia |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
| WO2017181193A2 (fr) * | 2016-04-15 | 2017-10-19 | The Uab Research Foundation | Procédés et composés permettant de stimuler la translecture de codons de terminaison prématurée |
| EP3512516A1 (fr) * | 2016-09-13 | 2019-07-24 | Marco Cipolli | Procédé de traitement du syndrome de shwachman-diamond |
| WO2019061324A1 (fr) | 2017-09-29 | 2019-04-04 | Curis Inc. | Formes cristallines d'immunomodulateurs |
| CA3078872A1 (fr) | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | Formes cristallines de 1,2,4-oxadiazole a substitution en position 3 |
| SG11202003625VA (en) | 2017-11-03 | 2020-05-28 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
| JP7339900B2 (ja) * | 2020-02-26 | 2023-09-06 | 新 井上 | 視野異常診断方法、視野異常診断装置 |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| CN118178408A (zh) * | 2024-03-22 | 2024-06-14 | 核工业总医院 | Ptc124在制备治疗血小板无力症的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW264475B (fr) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CA2449544A1 (fr) | 2001-06-08 | 2002-12-19 | Cytovia, Inc. | 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2003247610A1 (en) * | 2002-06-21 | 2004-01-06 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US6889231B1 (en) * | 2002-08-01 | 2005-05-03 | Oracle International Corporation | Asynchronous information sharing system |
| MXPA05001592A (es) | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| SI3345895T1 (sl) * | 2003-04-11 | 2020-03-31 | Ptc Therapeutics, Inc. | Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne in zdravljenje bolezni |
| WO2004110351A2 (fr) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Composes heterocycliques pour traiter le virus de l'hepatite c |
| EP1815206B1 (fr) * | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Composes de suppression de non-sens et procedes de leur utilisation |
| US20100130500A1 (en) * | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| ES2390804T3 (es) | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido |
| ZA200901782B (en) * | 2006-09-08 | 2010-06-30 | Ptc Therapeutics Inc | Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids |
| EP2559689B1 (fr) * | 2006-09-25 | 2017-11-29 | PTC Therapeutics, Inc. | Procédé de préparation pour formes cristallines de l'acide 3-[5-(2-fluorophényl)-[1,2,4]oxadiazol-3-yl] benzoïque |
| CA2942147C (fr) * | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Compositions pharmaceutiques et sels d'un acide benzoique 1,2,4-oxadiazole |
-
2007
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/fr active Active
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/ja active Active
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/es active Active
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/es unknown
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/es active Active
- 2007-09-24 SI SI200731750A patent/SI2076501T1/sl unknown
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/ko active IP Right Grant
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/zh active Pending
- 2007-09-24 AR ARP070104212A patent/AR062963A1/es not_active Application Discontinuation
- 2007-09-24 CA CA2663574A patent/CA2663574C/fr active Active
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/zh active Active
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/da active
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/pt not_active Application Discontinuation
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/fr active Active
- 2007-09-24 PL PL07838770T patent/PL2076501T3/pl unknown
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/xx unknown
- 2007-09-24 UA UAA200904012A patent/UA99600C2/ru unknown
- 2007-09-24 PL PL12185448T patent/PL2559689T3/pl unknown
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 PT PT78387701T patent/PT2076501E/pt unknown
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 MX MX2011007120A patent/MX344418B/es unknown
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/zh active Pending
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/fr active Application Filing
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/es active IP Right Grant
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/es not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/zh active
- 2007-09-26 TW TW103104823A patent/TWI496775B/zh active
-
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/no unknown
-
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
-
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
-
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
-
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/ja active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/xx unknown
-
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/lt unknown
-
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/ja active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/es unknown
-
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
-
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/ja not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en active Active
-
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/ja active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en not_active Abandoned
-
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207070A1 (en) | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]- benzoic acid 3-[5-(2-)-[124]-3-]- | |
| AR118922A2 (es) | Procesos para la preparación de ácidos de 1,2,4-oxadiazol benzoico | |
| ZA200809689B (en) | 1, 3, 4 -Oxadiazole derivatives as DGAT1 inhibitors | |
| HK1158627A1 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h- pyrrole derivatives as acid secretion inhibitors | |
| HK1203959A1 (en) | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2- | |
| IL180358A0 (en) | Crystalline form iv of linezolid | |
| PL2069374T3 (pl) | Krystaliczne solwaty pochodnych (1s)-1,5-anhydro-1-s-(3-((fenylo)metylo)fenylo)-d-glucytolu z alkoholami jako inhibitory sglt2 do leczenia cukrzycy | |
| IL207854A0 (en) | Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol | |
| IL198147A (en) | Seat-3 - [5- (2-fluoro-phenyl) - [1,2,4] oxadiazole-3-yl] of benzoic acid for the treatment, prevention or management of diseases caused by early termination codon | |
| HUE041326T2 (hu) | 5-(2,6-di-4-morfolinil-4-piridmidinil)-4-trifluorometilpiridin-2-amin kristályformái, egy PIK3 inhibitor | |
| IL183380A0 (en) | Crystalline forms of linezolid intermediate | |
| HK1189591A1 (en) | Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22- | |
| IL199239A0 (en) | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6- | |
| IL194351A0 (en) | 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides | |
| IL210923A0 (en) | A crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4,-triazol-3-yl)pyridine | |
| IL210924A0 (en) | A new crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine | |
| ZA200810321B (en) | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate |